The MENDEL|2 Randomized

The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of ...

The MENDEL-2 trial demonstrated robust reductions in LDL-C levels with evolocumab monotherapy in adults with hypercholesterolemia regardless of sex, age, race, ...

Anti-PCSK9 monotherapy for hypercholesterolemia - PubMed

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll ...

Anti-PCSK9 Monotherapy for Hypercholesterolemia: The MENDEL ...

Patients 18 to 80 years of age with fasting low-density lipoprotein cholesterol (LDL-C) ≥100 and <190 mg/dl and Framingham risk scores ≤10% were randomized (1:1 ...

The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of ...

Anti-PCSK9 Monotherapy for Hypercholesterolemia: The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of EvolocumabFree Access · View Full Text · PDF.

Efficacy, safety, and tolerability of a monoclonal antibody ... - PubMed

... (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012 Dec 8;380(9858):1995-2006. doi: 10.1016/S0140-6736(12) ...

Anti-PCSK9 monotherapy for hypercholesterolemia - Cochrane Library

... the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott ...

Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With ...

The GAUSS-2 (Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects) trial was a 12-week, double-blind study of randomized ...

Effect of Evolocumab or Ezetimibe Added to Moderate- or High ...

LAPLACE-2 was a 12-week, randomized, double-blind, placebo- and ezetimibe-controlled, phase 3, multicenter study examining the efficacy and ...

the MENDEL-2 randomized, controlled phase III clinical trial of ...

Conclusions. In the largest monotherapy trial using a PCSK9 inhibitor to date, evolocumab yielded significant LDL-C reductions compared with placebo or ...

the MENDEL-2 randomized, controlled phase III clinical trial of ...

Key Publications September 12, 2014. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of ...

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein ...

Findings In this prespecified analysis of a randomized clinical trial, 1 dose of inclisiran lowered time-averaged LDL-C levels over 1 year by ...

Anti-PCSK9 monotherapy for hypercholesterolemia - metajournal.com

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. ... 2 [MENDEL-2]; NCT01763827).

Amgen Announces Positive Top-Line Results From Phase 3 ...

The MENDEL-2 trial evaluated safety, tolerability and efficacy of ... randomized, multi-center, double-blind, double-dummy, stratified ...

Randomized, multicenter, phase 2 study (EVOLUTION) of ...

Abstract. Combinations of bortezomib (V) and dexamethasone (D) with either lenalidomide (R) or cyclophosphamide (C) have shown significant efficacy. This ...

Evolocumab for Hypercholesterolemia—MENDEL-2 Trial

This randomized phase III trial compared evolocumab, a fully human monoclonal antibody against PCSK9, with placebo and oral ezetimibe in 614 ...

Mendelian randomization - Wikipedia

Mendelian randomization (commonly abbreviated to MR) is a method using measured variation in genes to examine the causal effect of an exposure on an outcome.

A phase 2b, randomized, double-blind, placebo-controlled, clinical ...

In a UK cohort with biopsy-proven IgAN and proteinuria >0.5 g/d or estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m2, 50% of patients ...

A Prospective, Randomized Clinical Trial of Hemodynamic Support ...

Study Design and Patient Population. PROTECT II was a prospective, multicenter, randomized trial conducted in 112 sites in the United States, ...

Design Issues of Randomized Phase II Trials and a Proposal for ...

We present our own explorations into the possibilities of developing “phase II screening trials,” in which preliminary and nondefinitive randomized comparisons ...

Tilavonemab in early Alzheimer's disease: results from a phase 2 ...

In this 96-week, randomized, double-blind, placebo-controlled study (NCT02880956), patients aged 55–85 years meeting clinical criteria for early Alzheimer's ...